CSF Biomarker May Support Lewy Body Diagnosis - Summary - MDSpire
From the Journals

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

Share

Elevated cerebrospinal fluid (CSF) levels of DOPA decarboxylase (DDC) may aid in diagnosing Lewy body disorders, including Parkinson’s disease and dementia with Lewy bodies, based on a multicohort analysis. The study found that CSF DDC levels were higher in affected patients compared to both healthy controls and Alzheimer’s patients. Notably, DDC levels correlated with clinical features such as parkinsonian symptoms and visual hallucinations. Although the research highlights the potential of CSF DDC as a diagnostic biomarker, further exploration across varied patient populations is essential.

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

Hospital-Treated Infections Linked to Dementia Risk

Investigators identify 29 conditions associated with dementia risk in nationwide registry analysis.

Alzheimer’s Drug Lecanemab Works by “Switching On” the Brain’s Cleanup Cells

Study reveals Fc fragment of antibody is essential for activating microglia to clear amyloid plaques

  • April 7, 2026

  • 3 min